Fig. 5: Lipo-SM-CSS-Chol fortified the therapeutic delivery of DOX in orthotopic 4T1-Luc2 triple negative breast cancer (TNBC).

a A table delineating the physicochemical characterizations of DOX/Lipo with eq. 35 mol % Chol (eq. 64.4 mol % Chol for DOX/Lipo-PChcPC) and 5 mol % DSPE-PEG_2K (n = 3 independent experiments). b–f anti-TNBC effects in metastatic orthotopic 4T1-Luc2 tumor mouse model. A total of 2 × 10⁵ cells were injected into the 4^th mammary fat pad of BABL/c mice (n = 5 mice)⁸². On day 15, the mice with primary tumors ~200 mm³ (b) received an i.v. administration of various DOX/Lipo or Doxil at 15 mg DOX/kg. c Average tumor growth curves measured by a digital caliper. d mice BLI on day 15, 20, 29, and 35 by Lago optical imaging. Ex vivo lung metastasis BLI from all 5 mice in each group (e) and tumor-bearing mice images (f) were taken on day 35. Data in a (right portion), c (n = 5 mice) are expressed as mean ± s.d. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test; survival curves were compared using the log-rank Mantel–Cox test. Source data are provided as a Source Data file.